Company profile
KORRO BIO, INC.
NASDAQ:KRROBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06677307 | phase1_2 | terminated | 2025-01-13 | 2025-10-31 | Korro Bio, Inc. | A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110 |
| NCT07773246 | phase1_2 | recruiting | 2026-09-28 | 2027-08-01 | Korro Bio, Inc. | Phase 1/2 Study of KRRO-121 in Healthy Volunteers and Patients With UCD |
FDA applications (0)
No records yet.